JP2019528307A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528307A5
JP2019528307A5 JP2019511664A JP2019511664A JP2019528307A5 JP 2019528307 A5 JP2019528307 A5 JP 2019528307A5 JP 2019511664 A JP2019511664 A JP 2019511664A JP 2019511664 A JP2019511664 A JP 2019511664A JP 2019528307 A5 JP2019528307 A5 JP 2019528307A5
Authority
JP
Japan
Prior art keywords
phenyl
diamine
isopropylsulfonyl
pyrimidine
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019511664A
Other languages
English (en)
Japanese (ja)
Other versions
JP7094566B2 (ja
JP2019528307A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/048845 external-priority patent/WO2018044767A2/en
Publication of JP2019528307A publication Critical patent/JP2019528307A/ja
Publication of JP2019528307A5 publication Critical patent/JP2019528307A5/ja
Priority to JP2022096630A priority Critical patent/JP2022120151A/ja
Application granted granted Critical
Publication of JP7094566B2 publication Critical patent/JP7094566B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019511664A 2016-08-29 2017-08-28 Alk阻害剤としてのアミノピリミジン類 Active JP7094566B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022096630A JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29
US62/380,818 2016-08-29
PCT/US2017/048845 WO2018044767A2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as alk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096630A Division JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Publications (3)

Publication Number Publication Date
JP2019528307A JP2019528307A (ja) 2019-10-10
JP2019528307A5 true JP2019528307A5 (cg-RX-API-DMAC7.html) 2020-10-01
JP7094566B2 JP7094566B2 (ja) 2022-07-04

Family

ID=59846649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511664A Active JP7094566B2 (ja) 2016-08-29 2017-08-28 Alk阻害剤としてのアミノピリミジン類
JP2022096630A Pending JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022096630A Pending JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Country Status (11)

Country Link
US (2) US10709705B2 (cg-RX-API-DMAC7.html)
EP (2) EP3504203B1 (cg-RX-API-DMAC7.html)
JP (2) JP7094566B2 (cg-RX-API-DMAC7.html)
KR (1) KR102530871B1 (cg-RX-API-DMAC7.html)
CN (2) CN109715620B (cg-RX-API-DMAC7.html)
AU (2) AU2017319135B2 (cg-RX-API-DMAC7.html)
IL (1) IL264638B (cg-RX-API-DMAC7.html)
MX (2) MX389265B (cg-RX-API-DMAC7.html)
NZ (1) NZ751713A (cg-RX-API-DMAC7.html)
SG (2) SG10201914030UA (cg-RX-API-DMAC7.html)
WO (1) WO2018044767A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020024825A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Method for treating cancer by combination of fak/alk/ros1 inhibitor and egfr inhibitor
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
TWI769470B (zh) * 2019-06-25 2022-07-01 大陸商蘇州亞盛藥業有限公司 用於治療疾病的fak抑制劑和btk抑制劑的組合
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022063220A1 (en) * 2020-09-25 2022-03-31 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer
US20240316051A1 (en) * 2021-04-19 2024-09-26 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical combination and use thereof
JP2024544576A (ja) * 2021-12-09 2024-12-03 オンコビクス・カンパニー・リミテッド 癌細胞成長への抑制効果を示す新規ヘテロ環置換ピリミジン誘導体及びそれを含む医薬組成物
CN116332919B (zh) * 2022-03-30 2025-08-26 苏州亚盛药业有限公司 一种alk抑制剂化合物及其中间体的制备方法
AU2024210803A1 (en) 2023-01-20 2025-07-03 Ascentage Pharma (Suzhou) Co., Ltd. Crystal form of alk inhibitor or salt and solvate thereof, preparation method therefor, and use thereof
KR20250160958A (ko) * 2023-03-22 2025-11-14 어센테지 파마 (쑤저우) 컴퍼니 리미티드 약학적 조합 및 이의 응용

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SI2287156T1 (sl) 2003-08-15 2013-09-30 Novartis Ag 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema
CN100584832C (zh) * 2003-09-18 2010-01-27 诺瓦提斯公司 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类
DK2253614T3 (da) * 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
KR101238585B1 (ko) 2008-04-07 2013-02-28 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2011315831B2 (en) 2010-10-14 2015-01-22 Takeda Pharmaceutical Company Limited Methods for inhibiting cell proliferation in EGFR-driven cancers
MX2013008791A (es) * 2011-02-02 2013-10-07 Irm Llc Metodos para usar inhibidores de alk.
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
KR101656382B1 (ko) 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2019528307A5 (cg-RX-API-DMAC7.html)
EP2488178B1 (en) Combinations of a pi3k inhibitor and a mek inhibitor
JP2019511528A5 (cg-RX-API-DMAC7.html)
JP2015533177A5 (cg-RX-API-DMAC7.html)
JP2017008088A5 (cg-RX-API-DMAC7.html)
JP2020007311A5 (cg-RX-API-DMAC7.html)
CN103402519B (zh) 肿瘤治疗剂
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2019526615A5 (cg-RX-API-DMAC7.html)
JP2016523974A5 (cg-RX-API-DMAC7.html)
JP2017528487A5 (cg-RX-API-DMAC7.html)
JP2018526376A5 (cg-RX-API-DMAC7.html)
JP2016538313A5 (cg-RX-API-DMAC7.html)
JPWO2022173678A5 (cg-RX-API-DMAC7.html)
RU2016141934A (ru) Ингибиторы циклин-зависимой киназы 7 (cdk7)
JP2015508103A5 (cg-RX-API-DMAC7.html)
JP2011001339A5 (cg-RX-API-DMAC7.html)
JP2016522232A5 (cg-RX-API-DMAC7.html)
JP2019501195A5 (ja) 腫瘍を処置するための抗egfr組み合わせ
JP2015514808A5 (cg-RX-API-DMAC7.html)
JP2006507271A5 (cg-RX-API-DMAC7.html)
JP2015514806A5 (cg-RX-API-DMAC7.html)
RU2013147744A (ru) Дозированная лекарственная форма для перорального применения
JP2016525076A5 (cg-RX-API-DMAC7.html)
JP2015504067A5 (cg-RX-API-DMAC7.html)